GlassScriptPhysician profile
William K Debell
NPI 1184791329
$161,189.76
in general payments reported to CMS, 2019-2025
46 companies · $6,531 in 2025
The $6,531 reported for 2025 was more than what 88% of Endocrinology, Diabetes & Metabolism providers received nationally (typical 2025 total: $506).
See the full distribution for Endocrinology, Diabetes & Metabolism
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $21K · 2020: $55K · 2021: $29K · 2022: $28K · 2023: $12K · 2024: $9,953 · 2025: $6,531.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $22K · Food and Beverage: $4,250 · Travel and Lodging: $1,477 · Education: $150.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $22,406.00 |
| Food and Beverage | $4,250.11 |
| Travel and Lodging | $1,476.74 |
| Education | $149.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $77,474.67 | 2019-2024 | Rybelsus, Ozempic, Wegovy |
| Dexcom, INC. | $46,335.74 | 2019-2025 | Dexcom G7 Gss (161), Dexcom Stelo Glucose Biosensor, Dexcom G6 Transmitter |
| Tandem Diabetes Care, INC. | $18,826.61 | 2019-2024 | T:Slim X2 Insulin Pump With Control-Iq |
| Janssen Pharmaceuticals, INC | $7,399.72 | 2019-2021 | |
| Lilly USA, LLC | $1,989.46 | 2019-2024 | Mounjaro, Jardiance, Humulin |
| Sanofi-Aventis U.S. LLC | $1,315.11 | 2019-2024 | |
| Abbott Laboratories | $1,039.26 | 2019-2024 | Freestyle Libre 3, Freestyle Libre 2 |
| Esperion Therapeutics, INC. | $844.97 | 2020-2024 | Nexletol |
| Corcept Therapeutics | $833.85 | 2019-2023 | Korlym |
| Abbvie INC. | $713.13 | 2019-2024 | Ubrelvy, Vraylar, Synthroid |
| Amarin Pharma, INC. | $533.76 | 2019-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $397.08 | 2021-2024 | |
| Merck Sharp & Dohme LLC | $380.41 | 2019-2022 | |
| Astrazeneca Pharmaceuticals LP | $365.48 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $312.41 | 2022-2024 | Jardiance, Synjardy |
Show all 46 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Debell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.